NASDAQ:ATOS

Atossa Genetics (ATOS) Stock Price, News & Analysis

Atossa Genetics logo
$1.81 -0.09 (-4.74%)
Closing price 04:00 PM Eastern
Extended Trading
$1.81 +0.00 (+0.06%)
As of 06:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Atossa Genetics Stock (NASDAQ:ATOS)

Advanced

Key Stats

Today's Range
$1.79
▼
$1.92
50-Day Range
$1.90
▼
$2.91
52-Week Range
$1.70
▼
$14.85
Volume
42,714 shs
Average Volume
111,283 shs
Market Capitalization
$18.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.33
Consensus Rating
Moderate Buy

Company Overview

Atossa Therapeutics, Inc., formerly known as Atossa Genetics, is a clinical-stage biopharmaceutical company focused on developing treatments for breast cancer. The company is based in Seattle, Washington.

Its lead investigational drug candidate is (Z)-endoxifen, a form of endoxifen, which is an active metabolite of tamoxifen. Atossa is studying the candidate in clinical programs for breast cancer, including estrogen receptor-positive disease. The company has also explored oral and topical formulations.

Atossa was founded as Atossa Genetics and adopted the Atossa Therapeutics name as its focus shifted toward drug development. Its products remain investigational and are not approved for commercial use.

AI Generated. May Contain Errors.

Atossa Genetics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
45th Percentile Overall Score

ATOS MarketRank™: 
2.24737052323 of 5 stars

Atossa Genetics scored higher than 45% of companies evaluated by MarketBeat, and ranked 375th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Atossa Genetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Atossa Genetics has a consensus price target of $20.33, representing about 967.9% upside from its current price of $1.90.

  • Amount of Analyst Coverage

    Atossa Genetics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Atossa Genetics' stock forecast and price target.
  • Earnings Growth

    Earnings for Atossa Genetics are expected to grow in the coming year, from ($3.75) to ($2.78) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Atossa Genetics is -0.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Atossa Genetics is -0.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Atossa Genetics has a P/B Ratio of 0.87. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    5.85% of the float of Atossa Genetics has been sold short.
  • Short Interest Ratio / Days to Cover

    Atossa Genetics has a short interest ratio ("days to cover") of 7.59.
  • Change versus previous month

    Short interest in Atossa Genetics has recently decreased by 22.93%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Atossa Genetics does not currently pay a dividend.

  • Dividend Growth

    Atossa Genetics does not have a long track record of dividend growth.

  • Search Interest

    Only 3 people have searched for ATOS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Atossa Genetics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Atossa Genetics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    9.80% of the stock of Atossa Genetics is held by insiders.

  • Percentage Held by Institutions

    12.74% of the stock of Atossa Genetics is held by institutions.

  • Read more about Atossa Genetics' insider trading history.
Receive ATOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atossa Genetics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ATOS Stock News Headlines

Atossa Genetics (ATOS) Expected to Announce Earnings on Wednesday
Don’t delete this, read it today
Porter Stansberry has spent more than 30 years studying the economy and financial markets, and says he has never felt pressure like this. He believes the foundations beneath our way of life have cracked. One Nobel Prize winner has warned that the force behind it threatens to divide America. Stansberry points to rising living costs, deepening division and building anger as signs. His documentary, The Final Displacement, names the force and outlines what he believes you can do about it now.tc pixel
See More Headlines

ATOS Stock Analysis - Frequently Asked Questions

Atossa Genetics' stock was trading at $8.85 on January 1st, 2026. Since then, ATOS stock has decreased by 78.5% and is now trading at $1.9040.

Atossa Genetics Inc. (NASDAQ:ATOS) issued its quarterly earnings data on Tuesday, November, 10th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.86) by $0.30.

Atossa Genetics's stock reverse split on Monday, February 2nd 2026.The 1-15 reverse split was announced on Monday, January 26th 2026. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 30th 2026. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Atossa Genetics (ATOS) raised $6 million in an initial public offering on Thursday, November 8th 2012. The company issued 1,200,000 shares at $4.00-$6.00 per share.

Shares of ATOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Atossa Genetics investors own include NIO (NIO), NVIDIA (NVDA), Ocugen (OCGN), SNDL (SNDL), Vaxart (VXRT), Tesla (TSLA) and Bionano Genomics (BNGO).

Company Calendar

Last Earnings
11/10/2026
Today
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ATOS
CIK
1488039
Employees
14
Year Founded
2009

Price Target and Rating

High Price Target
$25.00
Low Price Target
$12.00
Potential Upside/Downside
+1,023.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.11)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$34.77 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-117.07%
Return on Assets
-96.08%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.35
Quick Ratio
5.35

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.18 per share
Price / Book
0.83

Miscellaneous

Outstanding Shares
9,980,000
Free Float
9,001,000
Market Cap
$18.06 million
Optionable
Optionable
Beta
1.38

Social Links

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (NASDAQ:ATOS) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners